Merck & Co., Inc. (MRK) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Merck & Company, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.097 Welcome to the Merck and Company Inc. Raleigh, New Jersey, USA third quarter sales 00:00:05.097 -- 00:00:09.983 and earnings conference call. At this time, all participants are in a listen-only mode 00:00:09.983 -- 00:00:13.768 until the question and answer session of today's conference. 00:00:13.768 -- 00:00:18.013 At that time, to ask a question, press star 1 on your phone and record your name at the 00:00:18.013 -- 00:00:23.519 prompt. This call is being recorded. If you have any objections, you may disconnect 00:00:23.519 -- 00:00:27.324 at this time. I would now like to turn the call over to Mr. 00:00:27.324 -- 00:00:31.248 Peter Dannenbaum. Senior Vice President, Investor Relations. 00:00:31.248 -- 00:00:33.531 Sir, you may begin. 00:00:33.531 -- 00:00:35.373 Thank you, Julie, and good morning, everyone. 00:00:35.373 -- 00:00:39.718 Welcome to the third quarter 2025 conference call for American Company Incorporated, 00:00:39.718 -- 00:00:44.603 Rahway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief 00:00:44.603 -- 00:00:49.168 Executive Officer, Caroline Litchfield, Chief Financial Officer, and Dr. 00:00:49.168 -- 00:00:53.593 Dean Lee, President of Research Labs. Before we get started, I'd like to point out that 00:00:53.593 -- 00:00:57.844 we have items in our GAAP results, such as acquisition-related charges, restructuring 00:00:57.844 -- 00:01:01.387 costs, and certain other items that we have excluded from our non-GAAP results. 00:01:01.387 -- 00:01:04.310 There is a reconciliation in our press release. 00:01:04.310 -- 00:01:07.413 I will also remind you that some of the statements that we make today may be considered 00:01:07.413 -- 00:01:10.977 forward-looking statements within the mean...